Formulation Design and Development of Anti-EGFR-BSA-CYP-SLNs In Situ Gel for Nasal Administration. Asian Journal of Pharmaceutics (AJP), [S. l.], v. 10, n. 04, 2016. DOI: 10.22377/ajp.v10i04.927. Disponível em: http://www.asiapharmaceutics.info/index.php/ajp/article/view/927. Acesso em: 14 apr. 2026.